Drug FDA Class II Terminated Sub/super-potent
Cefixime for Oral Suspension USP, 100 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA, NDC 68180-405-01
Lupin Pharmaceuticals Inc. Published Sep 4, 2024
Risk level
Class IIMay cause a temporary or reversible health problem; slight chance of serious harm.
Severity score 55/100
What should you do?
- Check whether you have this product, using the lot codes, UPCs, and dates listed below.
- Do not eat, serve, or sell the affected product.
- Return it to the place of purchase for a refund, or throw it away in a sealed bag so people and animals can’t get to it.
- Contact Lupin Pharmaceuticals Inc. or your place of purchase with questions, and see the source record below for full details.
Reason for recall
Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.
Hazards
Subpotency · primary
Affected products (1)
Cefixime for Oral Suspension USP, 100 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA, NDC 68180-405-01
CEFIXIME · 4554 bottles
NDC: 68180-405, 68180-407, 68180-416, 68180-423, 68180-405-01, 68180-407-03, 68180-407-04, 68180-416-08, 68180-416-11, 68180-423-11, 68180-423-08
Code info: Lot #: F201517, Exp 11/30/2024
Affected areas
Nationwide
Timeline
- InitiatedAug 21, 2024
- PublishedSep 4, 2024
- TerminatedApr 29, 2025
- Recall number
- D-0648-2024
- Agency
- U.S. Food and Drug Administration
- Country
- US
FDA records come from the openFDA drug enforcement-report dataset — the agency's full weekly enforcement list. Most entries are not issued as consumer press releases, so they won't appear on fda.gov/recalls or in a web search. The source record link above resolves this exact recall by its number.